"Europe's Access Dilemma" (1/5) - Europe Is Losing Access to New Medicines. Here’s Why.

Épisode de Pharma Minds par Nathalie Lahitte · 7 septembre 2026 · 31 min

What happens when making medicines cheaper in the US makes Europe less attractive for pharmaceutical innovation?

In this episode of Pharma minds, I speak with Christoffer Frendesen, a Brussels-based pharmaceutical journalist specializing in pricing and market access, about one of the most consequential questions facing Europe’s pharmaceutical market: what happens when the rules of global drug pricing change?

Trump’s Most Favored Nation (MFN) policy is putting pressure on pharmaceutical prices in the US. But the consequences may extend far beyond American patients, and Europe may end up paying part of the price.

Christoffer explains what he is hearing from industry and policy experts, and why delayed launches and higher prices in Europe may not be temporary effects. In some European countries, fewer new medicines are already being launched, raising a fundamental question about access to innovation.

We also explore:

◾️ Why Europe is struggling to speak with one voice on pharmaceutical pricing and market access

◾️ Whether national pricing and reimbursement systems are still sustainable

◾️ Whether a more coordinated European pricing and reimbursement system could improve access

◾️ Why the EU’s Biotech Act may not be enough to make Europe attractive for pharmaceutical R&D and manufacturing

◾️ And why the consequences of MFN could be much more permanent than a Trump presidency.

This is not simply a story about Trump or pricing. It is a conversation about Europe’s pharmaceutical competitiveness, access to innovation, and the choices Europe will have to make if it wants to remain an attractive market for the medicines of tomorrow.

To find Christoffer Frendesen: LinkedIn

Resources mentioned in the episode:

📌 Trump’s Most Favored Nation (MFN) policy: https://www.whitehouse.gov/fact-sheets/2026/08/fact-sheet-president-donald-j-trump-announces-deal-with-nine-additional-pharmaceutical-manufacturers-to-lower-drug-prices-for-americans/

📌 The EU Critical Medicines Act: https://health.ec.europa.eu/medicinal-products/critical-medicines-act_en

📌 The EU Biotech Act: https://health.ec.europa.eu/biotechnology/european-biotech-act_en

📌 GlobalData - March 2026

https://www.pharmaceutical-technology.com/analyst-comment/most-favored-nation-policy-early-insights-into-europe-response/

📌 IQVIA - July 2026

https://www.iqvia.com/locations/emea/blogs/2026/07/tracking-mfns-impact-on-innovative-medicine-launches

___

📩 Subscribe to the newsletter : https://nathalielahitte.substack.com/

Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Autres épisodes de « Pharma Minds »

À propos du podcast

Bienvenue dans Pharma minds, le podcast qui vous emmène dans une aventure captivante à travers la Pharma et la Santé d'aujourd'hui ! Je suis votre hôte, Nathalie Lahitte. Mon objectif ? Découvrir comment des personnalités influentes ont contribué à façonner ce secteur. À chaque épisode, nous…

Pharma Minds

Épisodes similaires

Radio et DAB+ : y aura-t-il un jour de la vidéo FM ? – Ça marque ! Le podcast qui décrypte les stratégies de communication digitale et les innovations du marketing éditorial
Webinaire / découvrir les ETF avec Amundi : comprendre, choisir et investir – Webinaire
Arrêt maladie, Indemnités limitées à un an : ces enjeux RH que les DRH doivent poser sur la table du CoDir dès maintenant – Capital Humain – Travail, ressources humaines et santé mentale
[AZIMUT ENTREPRENDRE | 1/3] - 15 000 abonnés sans montrer son visage - Safia Hadidi – Donne le Rythme
Bénédicte Henry, sa foi, <br>ses convictions et engagements – Les rencontres du père Jacques Thierry
1000 ads en une semaine : comment Flytex scale ses ads Meta avec l'IA – Le Rendez-vous E-commerce

Tous les épisodes de Pharma Minds · Plus de podcasts Business